ORIFARM GENERICS A/S: Financial statements 2025
CVR: 25674030
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
ORIFARM GENERICS A/S (CVR 25674030) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. That is an increase of 5.1% compared with the year before. The profit margin was 3.1%. Equity in the 2025 report amounted to DKK 496,304,000. The solvency ratio was 39.4%. The company had 247 employees in the financial year.
- Revenue
- DKK 2,463,585,000
- Gross Profit
- DKK 399,753,000
- Profit/Loss
- DKK 77,177,000
- Equity
- DKK 496,304,000
- Total Assets
- DKK 1,258,605,000
- Employees
- 247
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 2.5B | 399.8M | 77.2M | 496.3M | 247 |
| 2024 | 2.3B | 362M | 59.9M | 554.5M | 289 |
| 2023 | 2.1B | 344.5M | 62.9M | 494.6M | 289 |
| 2022 | 2.1B | 261.5M | 54.5M | 431.7M | 228 |
| 2021 | 1.8B | 329.3M | 150.1M | 527.3M | 181 |
Official annual report
How creditworthy is ORIFARM GENERICS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.12.a" issued by Amgros I/S worth 34,240,300 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.1390.b" issued by Amgros I/S worth 23,945,273 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.1203.a" issued by Amgros I/S worth 368,505,024 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.1290.b" issued by Amgros I/S worth 13,286,794 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.690.b" issued by Amgros I/S worth 217,081,515 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.1210.a" issued by Amgros I/S worth 104,066,115 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 1.617.b" issued by Amgros I/S worth 43,827,250 DKK.
ORIFARM GENERICS A/S has won the tender "Amgros 2026 2.790.b" issued by Amgros I/S worth 66,631,361 DKK.
As of October 20, 2025, Nicki Lund Kristensen has joined the board of directors of ORIFARM GENERICS A/S.
About ORIFARM GENERICS A/S
ORIFARM GENERICS A/S is a Danish company of the type Aktieselskab based in Odense S, founded in 2000. The company is registered under the industry Engroshandel med læge- og hospitalsartikler. The company was previously named COPYFARM A/S and A/S PSE 38 NR. 2228. The management consists of Thomas Brandhof. The board consists of Hans Carl Bøgh-Sørensen (chair), Birgitte Bøgh-Sørensen, Mads Fink Eriksen and Nicki Lund Kristensen. The company is owned by ORIFARM GENERICS HOLDING A/S. The company has 255 employees (2026). In 2025, the company reported revenue of DKK 2,463,585,000 and a net result of DKK 77,177,000 compared with DKK 59,860,000 the year before. Equity in the 2025 report amounted to DKK 496,304,000.